Anaxirone, a rationally synthesised triepoxide derivative, was given to 46 patients with metastatic colorectal cancer. Good risk patients received 800 mg/m(2) as a rapid intravenous injection every 4 weeks, whereas poor risk patients received 650 mg/m(2). Of 46 patients, 45 were evaulable for toxicity and 42 for efficacy analysis. There were 37/45 patients with poor risk, showing no difference in toxicity as compared to good risk patients. The major toxic effect was myelosuppression with 34% of all patients experiencing grade 3 or 4 leucopenia; thrombocytopenia was less frequent. Locoregional phlebitis occurred in 66% of the patients. There was no objective tumour response to anaxirone in 42 evaluable patients. Only 4 patients achieved stabilisation of the disease lasting maximally up to 248 days. Anaxirone is inactive in metastatic colorectal cancer.
Holdener, EE. ; Clavel, M. ; Sessa, C. ; Huinink, WT. ; Siegenthaler, P. ; et. al. Phase-ii Trial of Anaxirone (tgu) in Advanced Colorectal-cancer - An Eortc Early Clinical-trials Group (ectg) Study. In: European Journal of Cancer, Vol. 30A, no. 3, p. 394-395 (1994)